Source: Molecular and clinical oncology. Unidade: FM
Subjects: CARCINOMA HEPATOCELULAR, INIBIDORES DE ENZIMAS, SOBREVIDA
ABNT
FONSECA, Leonardo Gomes Da et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and clinical oncology, v. 3, n. 4, p. 793-796, 2015Tradução . . Disponível em: https://doi.org/10.3892/mco.2015.536. Acesso em: 16 nov. 2024.APA
Fonseca, L. G. D., Barroso-sousa, R., Bento, A. D. S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2015). Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and clinical oncology, 3( 4), 793-796. doi:10.3892/mco.2015.536NLM
Fonseca LGD, Barroso-sousa R, Bento ADSA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma [Internet]. Molecular and clinical oncology. 2015 ; 3( 4): 793-796.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3892/mco.2015.536Vancouver
Fonseca LGD, Barroso-sousa R, Bento ADSA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma [Internet]. Molecular and clinical oncology. 2015 ; 3( 4): 793-796.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3892/mco.2015.536